TY  - JOUR
AU  - Sudar, Emina
AU  - Zafirović, Sonja
AU  - Jovanović, Aleksandra
AU  - Trebaljevac, Jovana
AU  - Obradović, Milan M.
AU  - Cenić-Milošević, Desanka
AU  - Isenović, Esma R.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1580
AB  - Background: Nitric oxide (NO) is a potential biochemical, cardio-metabolic risk marker. The production of NO is catalyzed by different isoforms of enzymes, NO synthases (NOS). An altered NO level is associated with obesity, insulin resistance (IR), diabetes and cardiovascular diseases (CVD). Activity of NOS and NO production are regulated by various hormones under physiological and pathophysiological condition. Methods: Data used for this review were obtained by searching the electronic database [PUBMED/MEDLINE 1984 - May 2016]. Additionally, abstracts from national and international diabetes and cardiovascular related meetings were searched. The main data search terms were: nitric oxide, nitric oxide synthase, cardio-metabolic risk, obesity, diabetes, cardiovascular disease, estradiol and insulin-like growth factor-1. Results: In this review, we summarize the recent literature data related to the regulation of endothelial NOS (eNOS), inducible (iNOS) activity/expression, and thereby NO production by the hormones: estradiol (E2), and insulin-like growth factor-1 (IGF-1). Conclusion: Understanding the regulation of NO production by different hormones such as E2, and IGF-1 may provide novel and useful knowledge regarding how endothelial dysfunction (ED) is linked with cardio-metabolic alterations and diseases.
T2  - Current Pharmaceutical Design
T1  - Hormonal Regulation of Nitric Oxide (NO) in Cardio-metabolic Diseases
VL  - 23
IS  - 10
SP  - 1427
EP  - 1434
DO  - 10.2174/1381612823666170124124855
ER  - 

@article{
author = "Sudar, Emina and Zafirović, Sonja and Jovanović, Aleksandra and Trebaljevac, Jovana and Obradović, Milan M. and Cenić-Milošević, Desanka and Isenović, Esma R.",
year = "2017",
abstract = "Background: Nitric oxide (NO) is a potential biochemical, cardio-metabolic risk marker. The production of NO is catalyzed by different isoforms of enzymes, NO synthases (NOS). An altered NO level is associated with obesity, insulin resistance (IR), diabetes and cardiovascular diseases (CVD). Activity of NOS and NO production are regulated by various hormones under physiological and pathophysiological condition. Methods: Data used for this review were obtained by searching the electronic database [PUBMED/MEDLINE 1984 - May 2016]. Additionally, abstracts from national and international diabetes and cardiovascular related meetings were searched. The main data search terms were: nitric oxide, nitric oxide synthase, cardio-metabolic risk, obesity, diabetes, cardiovascular disease, estradiol and insulin-like growth factor-1. Results: In this review, we summarize the recent literature data related to the regulation of endothelial NOS (eNOS), inducible (iNOS) activity/expression, and thereby NO production by the hormones: estradiol (E2), and insulin-like growth factor-1 (IGF-1). Conclusion: Understanding the regulation of NO production by different hormones such as E2, and IGF-1 may provide novel and useful knowledge regarding how endothelial dysfunction (ED) is linked with cardio-metabolic alterations and diseases.",
journal = "Current Pharmaceutical Design",
title = "Hormonal Regulation of Nitric Oxide (NO) in Cardio-metabolic Diseases",
volume = "23",
number = "10",
pages = "1427-1434",
doi = "10.2174/1381612823666170124124855"
}

Sudar, E., Zafirović, S., Jovanović, A., Trebaljevac, J., Obradović, M. M., Cenić-Milošević, D.,& Isenović, E. R.. (2017). Hormonal Regulation of Nitric Oxide (NO) in Cardio-metabolic Diseases. in Current Pharmaceutical Design, 23(10), 1427-1434.
https://doi.org/10.2174/1381612823666170124124855

Sudar E, Zafirović S, Jovanović A, Trebaljevac J, Obradović MM, Cenić-Milošević D, Isenović ER. Hormonal Regulation of Nitric Oxide (NO) in Cardio-metabolic Diseases. in Current Pharmaceutical Design. 2017;23(10):1427-1434.
doi:10.2174/1381612823666170124124855 .

Sudar, Emina, Zafirović, Sonja, Jovanović, Aleksandra, Trebaljevac, Jovana, Obradović, Milan M., Cenić-Milošević, Desanka, Isenović, Esma R., "Hormonal Regulation of Nitric Oxide (NO) in Cardio-metabolic Diseases" in Current Pharmaceutical Design, 23, no. 10 (2017):1427-1434,
https://doi.org/10.2174/1381612823666170124124855 . .

TY  - JOUR
AU  - Radak, Đorđe J.
AU  - Đukić, Nenad
AU  - Tanasković, Slobodan
AU  - Obradović, Milan M.
AU  - Cenić-Milošević, Desanka
AU  - Isenović, Esma R.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1522
AB  - Endovascular surgery represents a minimally invasive procedure for the treatment of occlusive and aneurysmal arterial disease. However, it is followed by inflammatory response, with a rise in specific inflammatory biomarkers, such as C-reactive protein, serum amyloid A and fibrinogen. Shear stress during balloon inflation and vascular injury represents triggering events for the inflammatory process, stimulating the production of proinflammatory molecules and activation of circulating monocytes. The current literature indicates that stent implantation induces more prominent inflammatory reaction. Additionally, it has been shown that muscular arteries of femoropopliteal segment react to a greater extent to stent implantation, compared with elastic carotid or iliac arteries. The endovascular treatment of thoracic and abdominal aortic aneurysm is frequently followed with post-implantation inflammatory syndrome. Most recent findings point out that stent graft material plays a significant role in the inflammatory response, representing a challenge for clinicians. Future studies should consider the pathophysiology of the inflammatory response associated with endovascular procedures as well as predictors and risk factors including preventive strategies and therapeutic algorithms. Although the potential role of anti-inflammatory drugs after endovascular procedures has been observed, it needs to be validated in upcoming trials. The Neutrophil Lymphocyte Ratio, platelet count, Platelet-to-Lymphocyte Ratio and other biomarkers should be considered in future trials to assess the inflammatory response after endovascular procedures. Inflammatory markers may also become therapeutic targets.
T2  - Current Vascular Pharmacology
T1  - Should We be Concerned About the Inflammatory Response to Endovascular Procedures?
VL  - 15
IS  - 3
SP  - 230
EP  - 237
DO  - 10.2174/1570161115666170105121900
ER  - 

@article{
author = "Radak, Đorđe J. and Đukić, Nenad and Tanasković, Slobodan and Obradović, Milan M. and Cenić-Milošević, Desanka and Isenović, Esma R.",
year = "2017",
abstract = "Endovascular surgery represents a minimally invasive procedure for the treatment of occlusive and aneurysmal arterial disease. However, it is followed by inflammatory response, with a rise in specific inflammatory biomarkers, such as C-reactive protein, serum amyloid A and fibrinogen. Shear stress during balloon inflation and vascular injury represents triggering events for the inflammatory process, stimulating the production of proinflammatory molecules and activation of circulating monocytes. The current literature indicates that stent implantation induces more prominent inflammatory reaction. Additionally, it has been shown that muscular arteries of femoropopliteal segment react to a greater extent to stent implantation, compared with elastic carotid or iliac arteries. The endovascular treatment of thoracic and abdominal aortic aneurysm is frequently followed with post-implantation inflammatory syndrome. Most recent findings point out that stent graft material plays a significant role in the inflammatory response, representing a challenge for clinicians. Future studies should consider the pathophysiology of the inflammatory response associated with endovascular procedures as well as predictors and risk factors including preventive strategies and therapeutic algorithms. Although the potential role of anti-inflammatory drugs after endovascular procedures has been observed, it needs to be validated in upcoming trials. The Neutrophil Lymphocyte Ratio, platelet count, Platelet-to-Lymphocyte Ratio and other biomarkers should be considered in future trials to assess the inflammatory response after endovascular procedures. Inflammatory markers may also become therapeutic targets.",
journal = "Current Vascular Pharmacology",
title = "Should We be Concerned About the Inflammatory Response to Endovascular Procedures?",
volume = "15",
number = "3",
pages = "230-237",
doi = "10.2174/1570161115666170105121900"
}

Radak, Đ. J., Đukić, N., Tanasković, S., Obradović, M. M., Cenić-Milošević, D.,& Isenović, E. R.. (2017). Should We be Concerned About the Inflammatory Response to Endovascular Procedures?. in Current Vascular Pharmacology, 15(3), 230-237.
https://doi.org/10.2174/1570161115666170105121900

Radak ĐJ, Đukić N, Tanasković S, Obradović MM, Cenić-Milošević D, Isenović ER. Should We be Concerned About the Inflammatory Response to Endovascular Procedures?. in Current Vascular Pharmacology. 2017;15(3):230-237.
doi:10.2174/1570161115666170105121900 .

Radak, Đorđe J., Đukić, Nenad, Tanasković, Slobodan, Obradović, Milan M., Cenić-Milošević, Desanka, Isenović, Esma R., "Should We be Concerned About the Inflammatory Response to Endovascular Procedures?" in Current Vascular Pharmacology, 15, no. 3 (2017):230-237,
https://doi.org/10.2174/1570161115666170105121900 . .

TY  - JOUR
AU  - Obradović, Milan M.
AU  - Stanimirović, Julijana
AU  - Panić, Anastasija
AU  - Bogdanović, Nikola
AU  - Sudar, Emina
AU  - Cenić-Milošević, Desanka
AU  - Isenović, Esma R.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1581
AB  - Background: The sodium/potassium- adenosine- triphosphatase (Na+/K+-ATPase) is an important mediator in vasculature tone and contractility, and its abnormal regulation has been implicated in many diseases such as obesity, insulin resistance, diabetes, and hypertension. Decreased Na+/K+-ATPase abundance and its altered isoform expression induce cardiomyocytes death and cardiac dysfunction, possibly leading to the development of myocardial dilation and heart failure. Therefore, the regulation of Na+/K+-ATPase activity/expression could be important in treatment and possible prevention of cardio-metabolic diseases. A number of hormones and environmental factors regulate the function of Na+/K+-ATPase in response to changing cellular requirements. Estradiol and insulin like growth factor-1 (IGF-1) are among potent hormones that positively regulate Na+/K+-ATPase activity or de novo synthesis of alpha -and beta -subunits. Both estradiol and IGF-1 have a huge therapeutic potential in treatment of vasculopathy in cardio-metabolic diseases. Methods: We searched the MEDLINE and PUBMED databases for all English and non-English articles with an English abstract from April 1978 to May 2016. The main data search terms were: Na+/K+-ATPase; estradiol and Na+/K+-ATPase; estradiol, Na+/K+-ATPase and CVS; estradiol, Na+/K+-ATPase and CVD; estradiol, Na+/K+-ATPase and obesity; estradiol, Na+/K+-ATPase and diabetes; estradiol, Na+/K+-ATPase and hypertension; IGF-1; IGF-1 and Na+/K+-ATPase; IGF-1, Na+/K+-ATPase and CVS; IGF-1, Na+/K+-ATPase and CVD; IGF-1, Na+/K+-ATPase and obesity; IGF-1, Na+/K+-ATPase and diabetes; IGF-1, Na+/K+-ATPase and hypertension. Results: The present review discusses the latest data from animal and human studies which focus on the effects of estradiol and IGF-1 on Na+/K+-ATPase regulation in physiological and pathophysiological conditions in cardiovascular system. Conclusion: Understanding the molecular mechanisms of estradiol and IGF-1 action on Na+/K+-ATPase in humans, may help resolving outstanding issues and developing new strategies for the protection and treatment of cardiovascular diseases.
T2  - Current Pharmaceutical Design
T1  - Regulation of Na+/K+-ATPase by Estradiol and IGF-1 in Cardio-Metabolic Diseases
VL  - 23
IS  - 10
SP  - 1551
EP  - 1561
DO  - 10.2174/1381612823666170203113455
ER  - 

@article{
author = "Obradović, Milan M. and Stanimirović, Julijana and Panić, Anastasija and Bogdanović, Nikola and Sudar, Emina and Cenić-Milošević, Desanka and Isenović, Esma R.",
year = "2017",
abstract = "Background: The sodium/potassium- adenosine- triphosphatase (Na+/K+-ATPase) is an important mediator in vasculature tone and contractility, and its abnormal regulation has been implicated in many diseases such as obesity, insulin resistance, diabetes, and hypertension. Decreased Na+/K+-ATPase abundance and its altered isoform expression induce cardiomyocytes death and cardiac dysfunction, possibly leading to the development of myocardial dilation and heart failure. Therefore, the regulation of Na+/K+-ATPase activity/expression could be important in treatment and possible prevention of cardio-metabolic diseases. A number of hormones and environmental factors regulate the function of Na+/K+-ATPase in response to changing cellular requirements. Estradiol and insulin like growth factor-1 (IGF-1) are among potent hormones that positively regulate Na+/K+-ATPase activity or de novo synthesis of alpha -and beta -subunits. Both estradiol and IGF-1 have a huge therapeutic potential in treatment of vasculopathy in cardio-metabolic diseases. Methods: We searched the MEDLINE and PUBMED databases for all English and non-English articles with an English abstract from April 1978 to May 2016. The main data search terms were: Na+/K+-ATPase; estradiol and Na+/K+-ATPase; estradiol, Na+/K+-ATPase and CVS; estradiol, Na+/K+-ATPase and CVD; estradiol, Na+/K+-ATPase and obesity; estradiol, Na+/K+-ATPase and diabetes; estradiol, Na+/K+-ATPase and hypertension; IGF-1; IGF-1 and Na+/K+-ATPase; IGF-1, Na+/K+-ATPase and CVS; IGF-1, Na+/K+-ATPase and CVD; IGF-1, Na+/K+-ATPase and obesity; IGF-1, Na+/K+-ATPase and diabetes; IGF-1, Na+/K+-ATPase and hypertension. Results: The present review discusses the latest data from animal and human studies which focus on the effects of estradiol and IGF-1 on Na+/K+-ATPase regulation in physiological and pathophysiological conditions in cardiovascular system. Conclusion: Understanding the molecular mechanisms of estradiol and IGF-1 action on Na+/K+-ATPase in humans, may help resolving outstanding issues and developing new strategies for the protection and treatment of cardiovascular diseases.",
journal = "Current Pharmaceutical Design",
title = "Regulation of Na+/K+-ATPase by Estradiol and IGF-1 in Cardio-Metabolic Diseases",
volume = "23",
number = "10",
pages = "1551-1561",
doi = "10.2174/1381612823666170203113455"
}

Obradović, M. M., Stanimirović, J., Panić, A., Bogdanović, N., Sudar, E., Cenić-Milošević, D.,& Isenović, E. R.. (2017). Regulation of Na+/K+-ATPase by Estradiol and IGF-1 in Cardio-Metabolic Diseases. in Current Pharmaceutical Design, 23(10), 1551-1561.
https://doi.org/10.2174/1381612823666170203113455

Obradović MM, Stanimirović J, Panić A, Bogdanović N, Sudar E, Cenić-Milošević D, Isenović ER. Regulation of Na+/K+-ATPase by Estradiol and IGF-1 in Cardio-Metabolic Diseases. in Current Pharmaceutical Design. 2017;23(10):1551-1561.
doi:10.2174/1381612823666170203113455 .

Obradović, Milan M., Stanimirović, Julijana, Panić, Anastasija, Bogdanović, Nikola, Sudar, Emina, Cenić-Milošević, Desanka, Isenović, Esma R., "Regulation of Na+/K+-ATPase by Estradiol and IGF-1 in Cardio-Metabolic Diseases" in Current Pharmaceutical Design, 23, no. 10 (2017):1551-1561,
https://doi.org/10.2174/1381612823666170203113455 . .

TY  - JOUR
AU  - Trpković, Andreja
AU  - Resanović, Ivana
AU  - Stanimirović, Julijana
AU  - Radak, Đorđe J.
AU  - Mousa, Shaker A.
AU  - Cenić-Milošević, Desanka
AU  - Jevremovic, Danimir
AU  - Isenović, Esma R.
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/635
AB  - Atherosclerosis is a life-long illness that begins with risk factors, which in turn contribute to the development of subclinical disease, followed by the establishment of overt cardiovascular disease (CVD). Thrombotic-occlusive complications of atherosclerosis are among the most widespread and costly health problems. Oxidized low-density lipoprotein (OxLDL) plays an important role in atherogenesis by promoting an inflammatory environment and lipid deposition in the arterial wall. As cardiovascular events occur in individuals without common risk factors, there is a need for additional tools that may help in CVD risk assessment and management. The use of biomarkers has improved diagnostic, therapeutic and prognostic outcome in cardiovascular medicine. This review elaborates on the value of circulating OxLDL as a biomarker of CVD. Three enzyme-linked immunosorbent assays (4E6, DLH3 and E06) using murine monoclonal antibodies for determination of OxLDL blood levels have been developed. However, none of these assays are currently approved for routine clinical practice. We identified studies investigating OxLDL in CVD (measured by 4E6, DLH3 or E06 assay) by searching the PubMed database. Circulating OxLDL was found to be associated with all stages of atherosclerosis, from early atherogenesis to hypertension, coronary and peripheral arterial disease, acute coronary syndromes and ischemic cerebral infarction. The results of studies investigating the usefulness of OxLDL for CVD prediction were also summarized. Furthermore, OxLDL was found to be associated with pathologic conditions linked to CVD, including diabetes mellitus, obesity and metabolic syndrome (MetS). In addition, we have addressed the mechanisms by which OxLDL promotes atherogenesis, and the effects of antiatherogenic treatments on circulating OxLDL. Finally, we highlight the evidence suggesting that lipoprotein (a) [ Lp(a)] is the preferential carrier of oxidized phospholipids (OxPL) in human plasma. A strong association between OxPLapoB level (representing the content of OxPL on apolipoprotein B-100 particles, measured by E06 assay) and Lp(a) has been determined.
T2  - Critical Reviews in Clinical Laboratory Sciences
T1  - Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases
VL  - 52
IS  - 2
SP  - 70
EP  - 85
DO  - 10.3109/10408363.2014.992063
ER  - 

@article{
author = "Trpković, Andreja and Resanović, Ivana and Stanimirović, Julijana and Radak, Đorđe J. and Mousa, Shaker A. and Cenić-Milošević, Desanka and Jevremovic, Danimir and Isenović, Esma R.",
year = "2015",
abstract = "Atherosclerosis is a life-long illness that begins with risk factors, which in turn contribute to the development of subclinical disease, followed by the establishment of overt cardiovascular disease (CVD). Thrombotic-occlusive complications of atherosclerosis are among the most widespread and costly health problems. Oxidized low-density lipoprotein (OxLDL) plays an important role in atherogenesis by promoting an inflammatory environment and lipid deposition in the arterial wall. As cardiovascular events occur in individuals without common risk factors, there is a need for additional tools that may help in CVD risk assessment and management. The use of biomarkers has improved diagnostic, therapeutic and prognostic outcome in cardiovascular medicine. This review elaborates on the value of circulating OxLDL as a biomarker of CVD. Three enzyme-linked immunosorbent assays (4E6, DLH3 and E06) using murine monoclonal antibodies for determination of OxLDL blood levels have been developed. However, none of these assays are currently approved for routine clinical practice. We identified studies investigating OxLDL in CVD (measured by 4E6, DLH3 or E06 assay) by searching the PubMed database. Circulating OxLDL was found to be associated with all stages of atherosclerosis, from early atherogenesis to hypertension, coronary and peripheral arterial disease, acute coronary syndromes and ischemic cerebral infarction. The results of studies investigating the usefulness of OxLDL for CVD prediction were also summarized. Furthermore, OxLDL was found to be associated with pathologic conditions linked to CVD, including diabetes mellitus, obesity and metabolic syndrome (MetS). In addition, we have addressed the mechanisms by which OxLDL promotes atherogenesis, and the effects of antiatherogenic treatments on circulating OxLDL. Finally, we highlight the evidence suggesting that lipoprotein (a) [ Lp(a)] is the preferential carrier of oxidized phospholipids (OxPL) in human plasma. A strong association between OxPLapoB level (representing the content of OxPL on apolipoprotein B-100 particles, measured by E06 assay) and Lp(a) has been determined.",
journal = "Critical Reviews in Clinical Laboratory Sciences",
title = "Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases",
volume = "52",
number = "2",
pages = "70-85",
doi = "10.3109/10408363.2014.992063"
}

Trpković, A., Resanović, I., Stanimirović, J., Radak, Đ. J., Mousa, S. A., Cenić-Milošević, D., Jevremovic, D.,& Isenović, E. R.. (2015). Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. in Critical Reviews in Clinical Laboratory Sciences, 52(2), 70-85.
https://doi.org/10.3109/10408363.2014.992063

Trpković A, Resanović I, Stanimirović J, Radak ĐJ, Mousa SA, Cenić-Milošević D, Jevremovic D, Isenović ER. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. in Critical Reviews in Clinical Laboratory Sciences. 2015;52(2):70-85.
doi:10.3109/10408363.2014.992063 .

Trpković, Andreja, Resanović, Ivana, Stanimirović, Julijana, Radak, Đorđe J., Mousa, Shaker A., Cenić-Milošević, Desanka, Jevremovic, Danimir, Isenović, Esma R., "Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases" in Critical Reviews in Clinical Laboratory Sciences, 52, no. 2 (2015):70-85,
https://doi.org/10.3109/10408363.2014.992063 . .